214 related articles for article (PubMed ID: 34507552)
1. Adjuvant immunotherapy recommendations for stage III melanoma: physician and nurse interviews.
Livingstone A; Dempsey K; Stockler MR; Howard K; Long GV; Carlino MS; Menzies AM; Morton RL
BMC Cancer; 2021 Sep; 21(1):1014. PubMed ID: 34507552
[TBL] [Abstract][Full Text] [Related]
2. Should I Have Adjuvant Immunotherapy? An Interview Study Among Adults with Resected Stage 3 Melanoma and Their Partners.
Livingstone A; Milne D; Dempsey K; Muscat DM; Menzies AM; Howard K; Stockler MR; Morton RL
Patient; 2021 Sep; 14(5):635-647. PubMed ID: 33759137
[TBL] [Abstract][Full Text] [Related]
3. Preferences for Adjuvant Immunotherapy in Adults with Resected Stage III Melanoma-A Discrete Choice Experiment.
Livingstone A; Howard K; Menzies AM; Long GV; Stockler MR; Morton RL
Patient; 2023 Sep; 16(5):497-513. PubMed ID: 37351797
[TBL] [Abstract][Full Text] [Related]
4. Identifying challenges to implementation of clinical practice guidelines for sentinel lymph node biopsy in patients with melanoma in Australia: protocol paper for a mixed methods study.
Rapport F; Smith AL; Cust AE; Mann GJ; Watts CG; Gyorki DE; Henderson M; Hong AM; Kelly JW; Long GV; Mar VJ; Morton RL; Saw RP; Scolyer RA; Spillane AJ; Thompson JF; Braithwaite J
BMJ Open; 2020 Feb; 10(2):e032636. PubMed ID: 32111612
[TBL] [Abstract][Full Text] [Related]
5. Balancing the Hype with Reality: What Do Patients with Advanced Melanoma Consider When Making the Decision to Have Immunotherapy?
Wong A; Billett A; Milne D
Oncologist; 2019 Nov; 24(11):e1190-e1196. PubMed ID: 31015314
[TBL] [Abstract][Full Text] [Related]
6. Adjuvant immunotherapy with tumor infiltrating lymphocytes and interleukin-2 in patients with resected stage III and IV melanoma.
Ridolfi L; Ridolfi R; Riccobon A; De Paola F; Petrini M; Stefanelli M; Flamini E; Ravaioli A; Verdecchia GM; Trevisan G; Amadori D
J Immunother; 2003; 26(2):156-62. PubMed ID: 12616107
[TBL] [Abstract][Full Text] [Related]
7. Management options for metastatic melanoma in the era of novel therapies: a primer for the practicing dermatologist: part I: Management of stage III disease.
Fox MC; Lao CD; Schwartz JL; Frohm ML; Bichakjian CK; Johnson TM
J Am Acad Dermatol; 2013 Jan; 68(1):1.e1-9; quiz 10-12. PubMed ID: 23244383
[TBL] [Abstract][Full Text] [Related]
8. The role of adjuvant therapy in melanoma management.
Barth A; Morton DL
Cancer; 1995 Jan; 75(2 Suppl):726-34. PubMed ID: 7805001
[TBL] [Abstract][Full Text] [Related]
9. Comorbidity burden on receipt of adjuvant immunotherapy and survival in patients with stage III melanoma: an analysis of the National Cancer Database.
Freeman SC; Satish M; Walters RW
Int J Dermatol; 2020 Nov; 59(11):1381-1390. PubMed ID: 32592609
[TBL] [Abstract][Full Text] [Related]
10. Shared care in the follow-up of early-stage melanoma: a qualitative study of Australian melanoma clinicians' perspectives and models of care.
Rychetnik L; Morton RL; McCaffery K; Thompson JF; Menzies SW; Irwig L
BMC Health Serv Res; 2012 Dec; 12():468. PubMed ID: 23253951
[TBL] [Abstract][Full Text] [Related]
11. From decision to reflection: understanding the experiences and unmet care needs of patients treated with immunotherapy for melanoma in the adjuvant or metastatic setting.
Kamminga NCW; van der Veldt AAM; Wakkee M; van den Berge FR; van der Beek LAA; Joosen MCW; Joosse A; de Joode K; Nijsten TEC; Lugtenberg M
BMC Cancer; 2024 May; 24(1):662. PubMed ID: 38816701
[TBL] [Abstract][Full Text] [Related]
12. Variation in the depth of excision of melanoma: A survey of US physicians.
DeFazio JL; Marghoob AA; Pan Y; Dusza SW; Khokhar A; Halpern A
Arch Dermatol; 2010 Sep; 146(9):995-9. PubMed ID: 20644028
[TBL] [Abstract][Full Text] [Related]
13. Deciding on adjuvant chemotherapy for elderly patients with stage III colon cancer: a qualitative insight into the perspectives of surgeons and medical oncologists.
van Erning FN; Janssen-Heijnen ML; Creemers GJ; Pruijt HF; Maas HA; Lemmens VE
J Geriatr Oncol; 2015 May; 6(3):219-24. PubMed ID: 25703856
[TBL] [Abstract][Full Text] [Related]
14. Contemporary management of locoregionally advanced melanoma in Australia and New Zealand and the role of adjuvant systemic therapy.
Smithers BM; Saw RPM; Gyorki DE; Martin RCW; Atkinson V; Haydon A; Roberts-Thomson R; Thompson JF
ANZ J Surg; 2021 Aug; 91 Suppl 2():3-13. PubMed ID: 34288329
[TBL] [Abstract][Full Text] [Related]
15. [Adjuvant adoptive immunotherapy in patients with stage III and resected stage IV melanoma: a pilot study].
Verdecchia GM; Ridolfi L; Ridolfi R; Riccobon A; Bertagni A; Vagliasindi A; Petrini M; Stefanelli M; Milandri C; Amadori D
Tumori; 2003; 89(4 Suppl):298-300. PubMed ID: 12903626
[TBL] [Abstract][Full Text] [Related]
16. Adjuvant NY-ESO-1 vaccine immunotherapy in high-risk resected melanoma: a retrospective cohort analysis.
Lattanzi M; Han J; Moran U; Utter K; Tchack J; Sabado RL; Berman R; Shapiro R; Huang HH; Osman I; Bhardwaj N; Pavlick AC
J Immunother Cancer; 2018 May; 6(1):38. PubMed ID: 29773080
[TBL] [Abstract][Full Text] [Related]
17. Decision-making under clinical uncertainty: An in-depth examination of provider perspectives on adjuvant chemotherapy for stage II colon cancer.
Shelton RC; Brotzman LE; Crookes DM; Robles P; Neugut AI
Patient Educ Couns; 2019 Feb; 102(2):284-290. PubMed ID: 30262401
[TBL] [Abstract][Full Text] [Related]
18. Developing indications for the use of sentinel lymph node biopsy and adjuvant high-dose interferon alfa-2b in melanoma.
Dubois RW; Swetter SM; Atkins M; McMasters K; Halbert R; Miller SJ; Shiell R; Kirkwood J
Arch Dermatol; 2001 Sep; 137(9):1217-24. PubMed ID: 11559220
[TBL] [Abstract][Full Text] [Related]
19. Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial.
Amaria RN; Prieto PA; Tetzlaff MT; Reuben A; Andrews MC; Ross MI; Glitza IC; Cormier J; Hwu WJ; Tawbi HA; Patel SP; Lee JE; Gershenwald JE; Spencer CN; Gopalakrishnan V; Bassett R; Simpson L; Mouton R; Hudgens CW; Zhao L; Zhu H; Cooper ZA; Wani K; Lazar A; Hwu P; Diab A; Wong MK; McQuade JL; Royal R; Lucci A; Burton EM; Reddy S; Sharma P; Allison J; Futreal PA; Woodman SE; Davies MA; Wargo JA
Lancet Oncol; 2018 Feb; 19(2):181-193. PubMed ID: 29361468
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
